Buckwheat anaphylaxis is commonly recognized in Europe and Asia, and there is only one case reported in Taiwan so far. Here, we report a case of biphasic buckwheat anaphylaxis in a 57 year-old male patient who lost consciousness twice in the same day after having buckwheat noodles. The serum test shows that Dermatophagoides pteronyssinus (Dp) immunoglobulin E (IgE) (42.4 kU/L) and buckwheat-specific IgE (81.5 kU/L) are unusually high. Although biphasic buckwheat anaphylaxis is rare, we should still be aware the second episode could be life-threatening and happen within a day after the exposure to the buckwheat antigen.
Introduction
Buckwheat (Fagopyrum esculentum) and tartary buckwheat (Fagopyrum tartaricum) are widely used in traditional Japanese, Korean, and European diets. 1 There is a growing consumption of health food in Taiwan, including buckwheat products. Besides, buckwheat is gluten-free and serves as a good alternative for celiac disease sufferers and other people intolerant of wheat flour. 2 Direct ingestion is not the only pathway to cause buckwheat anaphylaxis, which could also be caused by buckwheat contamination during food preparation. 2 Therefore, the whole procedure of food preparation should be taken carefully for buckwheat-allergic patients. The incidence of buckwheat allergy is 0.22% in children. 3 However, as a hidden antigen, the risk of buckwheat ingestion is usually underestimated.
Buckwheat is a rare allergen in Taiwan. The only case report is of a woman with asthma who had anaphylactic shock, generalized urticaria, and an acute exacerbation of asthma five minutes after ingesting buckwheat. 4 To our knowledge, this is the first report of biphasic buckwheat anaphylactic shock in Taiwan.
Case report
A 57 year-old man had fainting, loss of consciousness and skin rash with wheal and flare developing 40 minutes after having buckwheat noodles. Immediately, he was brought to the emergency department by colleagues and was discharged two hours later after intramuscular (IM) injection of 0.5 mg epinephrine and 10 mg chlorphenamine. However, throat itching, generalized wheal and flare skin lesions, angioedema, fainting, and loss of consciousness were noted again within two hours of his return to his office. He was brought to the emergency department again right away. IM injection of 0.5 mg epinephrine and 10 mg chlorphenamine were again given at the emergency room, and he was discharged after a 2-hour observation. He followed up in our outpatient department for further diagnosis and management one week later.
He has a past history of tongue numbness, dizziness, wheal and flare skin rash with pruritis, palpitations, and loss of consciousness that developed at the age of 54 within 30 minutes after ingesting buckwheat noodles. Besides, generalized wheal and flare skin rash developed at the age of 55 within 1 hour after ingesting whole grain bread (including buckwheat). There were no allergic symptoms (i.e., urticaria, itching throat, fainting, or angioedema) noted in his medical history after ingesting noodles or bread not containing buckwheat. The patient's history was negative for drug allergy.
His serum was tested for specific IgE to Dp, cat and dog danders, cockroach, and food allergens including egg white, milk, fish, wheat, and buckwheat ( Table 1) with Pharmacia CAP system (Uppsala, Sweden), and only test results for Dp (42.4 kU/L, class 4) and buckwheat-specific IgE (81.5 kU/L, class 5) were positive. Other blood test results were: hemoglobin 14 gm/dL, hematocrit 40.9%, white blood cell count 11,100/μL, platelet count 351,000/μL, blood sugar 97 mg/dL, glycosylated hemoglobin (HbA1c) 5.8%, and IgE 950 IU/mL.
Discussion
IgE-mediated hypersensitivity to buckwheat is common in Korea, Japan, and some other Asian countries. 4 It is also reported that the proportion of anaphylaxis was highest in the patients allergic to buckwheat in Korea. Therefore, the risk of buckwheat anaphylaxis should not be underestimated. We summarize ( Table 2 ) the most common foods causing anaphylaxis, the prevalence of biphasic anaphylaxis, and the fatal cases in Asia from recent reports. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Biphasic anaphylaxis refers to the second episode of anaphylaxis and has been reported to develop in up to 20% of reactions. 15 There are no significant differences in baseline characteristics between patients with and without biphasic anaphylaxis, such as atopic diseases, triggers, precipitating factors (i.e., food, exercise, and medication), clinical manifestations, and treatments. 6 However, it is known that the risk of biphasic anaphylaxis increases with multiple doses of epinephrine during the initial treatment. For instance, in one of the reports, pediatric patients received a dose of 0.01 mg/ kg (maximum dose = 0.5 mg). 7 The risk also increases in pediatric patients taking a longer time to resolve from the first episode compared to the uniphasic reactors 16 or having delayed administration of epinephrine. 17 Additionally, we noted a delayed onset for the development of symptoms after the initial exposure to the antigen, 18 and oral ingestion of antigen has been noted as a potential predisposing factor in two reports. 18, 20 Although double-blind placebo-controlled food challenge (DBPCFC) is the gold standard to confirm buckwheat allergy, it is time-consuming and can be life-threatening. This risk can be avoided with measuring the food-specific IgE concentration in serum. Thus, the detection of crude buckwheat extract -specific IgE by ImmunoCAP (f11) (Phadia AB, Uppsala, Sweden) is widely used to diagnose buckwheat allergy. 21 Sohn et al. concluded that a cutoff level of 1.26 kU/L of specific IgE for buckwheat was adequate for diagnosis in children with a strong clinical history. 26 In this report, we utilized Pharmacia CAP to obtain the buckwheat-specific IgE concentration of 81.5 kU/L in serum, which is significantly higher than the cutoff value (1.26 kU/L) of the method mentioned above. The buckwheat-specific IgE concentration is extremely high, which is compatible with his severe allergic symptoms. We thought it was dangerous for the patient to try an oral food challenge. The specific IgE of wheat is significantly low (< 0.35 IU/L, class 0) in this patient. Besides, food containing wheat is common in Taiwan, and there are no related allergic symptoms found in the patient's history. Hence, we conclude that the patient is allergic to buckwheat without further examinations (e.g., the measurement of the major allergen in wheat, omega 5-gliadin).
Adrenaline (epinephrine) is essential to all patients experiencing anaphylaxis, which should be given by IM injection into the mid-outer thigh. The safety profile of IM adrenaline is excellent, although patients may experience transient pallor, palpitations, and headache. IM adrenaline (1 mg/mL) should be given at a dose of 0.01 mL/kg of body weight to a maximum total dose of 0.5 mL. When using adrenaline auto-injectors, patients weighing 7.5-25 kg should receive a 0.15 mg dose with patients being moved to a 0.3 mg dose at 25-30 kg. The adrenaline dose can be repeated after at least a 5-minute interval. 15 Oral (PO) or intravenous (IV) glucocorticosteroids are commonly used in anaphylaxis and are thought to possibly prevent protracted anaphylaxis symptoms, particularly in patients with concomitant asthma and biphasic reactions. 9 The dose of hydrocortisone for adults and children depends on age: > 12 years and adults: 200 mg IM or IV slowly; > 6 to 12 years: 100 mg IM or IV slowly; > 6 months to 6 years: 50 mg IM or IV slowly; < 6 months: 25 mg IM or IV slowly. 23 With regard to monitoring and discharge arrangement, patients who present with respiratory compromise should be closely monitored for at least 6-8 hours, and patients who present with hypotension require close monitoring for at least 12-24 hours. 6 The education is important to the patients, including the of early recognition of anaphylactic symptoms and the avoidance of direct and indirect contacts with allergens, especially food allergens. Before discharge, the risk of future reactions should be assessed and an adrenaline auto-injector prescribed to those at risk of recurrence. Patients should be provided with a discharge advice sheet, including allergen avoidance measures (where possible) and instructions for when and how to use the adrenaline auto-injector. Referral to an allergy specialist is recommended to investigate possible triggers, assess and, where possible, to intervene to minimize the risk of further reactions, and ensure that patients and caregivers are optimally equipped and trained to manage any further reactions; and, if food is involved, referral to a registered dietitian.
